Greenhaven Road Capital released its Q2 2025 investor letter, reporting a +14% return for the quarter and under +1% YTD. Cellebrite DI Ltd. (NASDAQ: CLBT) was highlighted as a stock with 13.32% one-month return and $16.16 per share on August 18, 2025, with a market cap of $3.951 billion.

In the investor letter, Greenhaven Road Capital discussed Cellebrite DI Ltd. (NASDAQ: CLBT), stating concerns about delayed purchases due to US federal budget uncertainty. Despite this, the company’s business is not declining, with Q1 Annual Recurring Revenue up 23% year-over-year.

Cellebrite DI Ltd. (NASDAQ: CLBT) reported revenue of $113.3 million in Q2 2025, up 18% from the previous year, driven by a 21% growth in subscription revenue. The stock is not among the 30 most popular stocks among hedge funds, but it offers potential for investment, alongside other AI stocks with greater upside potential and lower downside risk.

Read more at Yahoo Finance: Cellebrite (CLBT) Fell on Investors’ Worry that US Federal Budget Uncertainty Could Delay Purchases